Biotechnology stocks are high-risk, high-reward investments in companies developing novel therapeutics, gene therapies, and biologics. Our AI examines pipeline strength, clinical trial progress, cash runway, and partnership deals from SEC filings to identify the most promising biotech investments.
Best Biotechnology Stocks to Buy in 2026
Top-rated biotechnology stocks ranked by AI confidence score. Dual AI analysis (Claude + ChatGPT) based on SEC 10-K and 10-Q filings. Last Updated: April 2026
NBIX
Confidence
84%
EXEL
Confidence
82%
KRYS
Confidence
80%
ELMD
Confidence
80%
MDT
Confidence
80%
NAGE
Confidence
79%
FTLF
Confidence
74%
BDTX
Confidence
74%
BCRX
Confidence
72%
BLFS
Confidence
67%
IMCR
Confidence
66%
HALO
Confidence
64%
All Biotechnology Stocks (196)
| Ticker | Company | AI Rating | Confidence | Action |
|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | STRONG SELL | 97% | View Analysis → |
| NIMU | NON INVASIVE MONITORING SYSTEMS INC /FL/ | STRONG SELL | 96% | View Analysis → |
| IRME | IR-Med, Inc. | STRONG SELL | 96% | View Analysis → |
| ENDV | ENDONOVO THERAPEUTICS, INC. | STRONG SELL | 96% | View Analysis → |
| CFOO | China Foods Holdings Ltd. | STRONG SELL | 96% | View Analysis → |
| BKHAR | Black Hawk Acquisition Corp | STRONG SELL | 96% | View Analysis → |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | STRONG SELL | 96% | View Analysis → |
| ARMP | Armata Pharmaceuticals, Inc. | STRONG SELL | 96% | View Analysis → |
| AIM | AIM ImmunoTech Inc. | STRONG SELL | 96% | View Analysis → |
| SCLXW | Scilex Holding Co | STRONG SELL | 95% | View Analysis → |
| POSC | POSITRON CORP | STRONG SELL | 95% | View Analysis → |
| PLUR | Pluri Inc. | STRONG SELL | 95% | View Analysis → |
| PLSH | PANACEA LIFE SCIENCES HOLDINGS, INC. | STRONG SELL | 95% | View Analysis → |
| AIBT | AIBOTICS, INC. | STRONG SELL | 95% | View Analysis → |
| NTRR | NEUTRA CORP. | STRONG SELL | 94% | View Analysis → |
| CRGT | Cortigent, Inc. | SELL | 94% | View Analysis → |
| CPMV | Mosaic ImmunoEngineering Inc. | STRONG SELL | 94% | View Analysis → |
| CEROW | CERO THERAPEUTICS HOLDINGS, INC. | STRONG SELL | 94% | View Analysis → |
| CBDY | Target Group Inc. | STRONG SELL | 94% | View Analysis → |
| APTOF | Aptose Biosciences Inc. | STRONG SELL | 94% | View Analysis → |
| FTII | FutureTech II Acquisition Corp. | STRONG SELL | 93% | View Analysis → |
| EXOZ | EXOZYMES INC. | STRONG SELL | 93% | View Analysis → |
| ESLAW | Estrella Immunopharma, Inc. | STRONG SELL | 93% | View Analysis → |
| ENZN | ENZON PHARMACEUTICALS, INC. | STRONG SELL | 93% | View Analysis → |
| BCAB | BioAtla, Inc. | STRONG SELL | 93% | View Analysis → |
| SNYR | Synergy CHC Corp. | STRONG SELL | 92% | View Analysis → |
| SLDB | Solid Biosciences Inc. | STRONG SELL | 92% | View Analysis → |
| POCI | PRECISION OPTICS CORPORATION, INC. | STRONG SELL | 92% | View Analysis → |
| PHGE | BiomX Inc. | STRONG SELL | 92% | View Analysis → |
| GTHP | GUIDED THERAPEUTICS INC | STRONG SELL | 92% | View Analysis → |
| GPLB | Green Planet Bio Engineering Co. Ltd. | STRONG SELL | 92% | View Analysis → |
| INKT | MiNK Therapeutics, Inc. | STRONG SELL | 92% | View Analysis → |
| EDIT | Editas Medicine, Inc. | STRONG SELL | 92% | View Analysis → |
| DBVTF | DBV Technologies S.A. | STRONG SELL | 92% | View Analysis → |
| CUBT | Curative Biotechnology Inc | SELL | 92% | View Analysis → |
| CRIS | CURIS INC | STRONG SELL | 92% | View Analysis → |
| CLDWW | Calidi Biotherapeutics, Inc. | STRONG SELL | 92% | View Analysis → |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | STRONG SELL | 92% | View Analysis → |
| BCDA | BioCardia, Inc. | STRONG SELL | 92% | View Analysis → |
| ALEC | Alector, Inc. | STRONG SELL | 92% | View Analysis → |
| MGTX | MeiraGTx Holdings plc | STRONG SELL | 91% | View Analysis → |
| DNABW | Ginkgo Bioworks Holdings, Inc. | STRONG SELL | 91% | View Analysis → |
| CVM | CEL SCI CORP | STRONG SELL | 91% | View Analysis → |
| CRDF | Cardiff Oncology, Inc. | STRONG SELL | 91% | View Analysis → |
| ATRA | Atara Biotherapeutics, Inc. | STRONG SELL | 91% | View Analysis → |
| ALGS | Aligos Therapeutics, Inc. | STRONG SELL | 91% | View Analysis → |
| RAPH | Raphael Pharmaceutical Inc. | STRONG SELL | 90% | View Analysis → |
| OTLK | Outlook Therapeutics, Inc. | STRONG SELL | 90% | View Analysis → |
| NDRA | ENDRA Life Sciences Inc. | STRONG SELL | 90% | View Analysis → |
| LIMNW | Liminatus Pharma, Inc. | STRONG SELL | 90% | View Analysis → |
| NUWE | Nuwellis, Inc. | STRONG SELL | 90% | View Analysis → |
| MGX | Metagenomi Therapeutics, Inc. | STRONG SELL | 90% | View Analysis → |
| FNCH | Finch Therapeutics Group, Inc. | STRONG SELL | 90% | View Analysis → |
| DFTX | Definium Therapeutics, Inc. | SELL | 90% | View Analysis → |
| CV | CapsoVision, Inc | STRONG SELL | 90% | View Analysis → |
| CRBU | Caribou Biosciences, Inc. | SELL | 90% | View Analysis → |
| ATYR | aTYR PHARMA INC | STRONG SELL | 90% | View Analysis → |
| IBRX | ImmunityBio, Inc. | STRONG SELL | 89% | View Analysis → |
| ENTX | Entera Bio Ltd. | SELL | 89% | View Analysis → |
| BON | Bon Natural Life Ltd | SELL | 89% | View Analysis → |
| SNTI | Senti Biosciences, Inc. | STRONG SELL | 88% | View Analysis → |
| SLXNW | Silexion Therapeutics Corp | STRONG SELL | 88% | View Analysis → |
| SGMO | SANGAMO THERAPEUTICS, INC | STRONG SELL | 88% | View Analysis → |
| RVMDW | Revolution Medicines, Inc. | STRONG SELL | 88% | View Analysis → |
| QTIWW | QT IMAGING HOLDINGS, INC. | STRONG SELL | 88% | View Analysis → |
| OCGN | Ocugen, Inc. | STRONG SELL | 88% | View Analysis → |
| INBX | Inhibrx Biosciences, Inc. | STRONG SELL | 88% | View Analysis → |
| RGNX | REGENXBIO Inc. | STRONG SELL | 88% | View Analysis → |
| INMB | Inmune Bio, Inc. | SELL | 88% | View Analysis → |
| FATE | FATE THERAPEUTICS INC | SELL | 88% | View Analysis → |
| ELUT | ELUTIA INC. | SELL | 88% | View Analysis → |
| ECOR | electroCore, Inc. | SELL | 88% | View Analysis → |
| CRLBF | Cresco Labs Inc. | SELL | 88% | View Analysis → |
| ARTV | Artiva Biotherapeutics, Inc. | SELL | 88% | View Analysis → |
| SRZNW | Surrozen, Inc./DE | STRONG SELL | 87% | View Analysis → |
| PLX | Protalix BioTherapeutics, Inc. | STRONG SELL | 87% | View Analysis → |
| DYAI | DYADIC INTERNATIONAL INC | SELL | 87% | View Analysis → |
| CADL | Candel Therapeutics, Inc. | SELL | 87% | View Analysis → |
| CABA | Cabaletta Bio, Inc. | SELL | 87% | View Analysis → |
| LXEO | Lexeo Therapeutics, Inc. | SELL | 86% | View Analysis → |
| INTS | INTENSITY THERAPEUTICS, INC. | SELL | 86% | View Analysis → |
| ESMC | ESCALON MEDICAL CORP | SELL | 86% | View Analysis → |
| DNLI | Denali Therapeutics Inc. | SELL | 86% | View Analysis → |
| CURLF | Curaleaf Holdings, Inc. | SELL | 86% | View Analysis → |
| CHUC | Charlie's Holdings, Inc. | SELL | 86% | View Analysis → |
| ALLO | Allogene Therapeutics, Inc. | SELL | 86% | View Analysis → |
| STEX | Streamex Corp. | STRONG SELL | 85% | View Analysis → |
| PTHS | Pelthos Therapeutics Inc. | STRONG SELL | 85% | View Analysis → |
| PROK | PROKIDNEY CORP. | STRONG SELL | 85% | View Analysis → |
| PCVX | Vaxcyte, Inc. | STRONG SELL | 85% | View Analysis → |
| JUSHF | Jushi Holdings Inc. | STRONG SELL | 85% | View Analysis → |
| NRXS | Neuraxis, INC | STRONG SELL | 85% | View Analysis → |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | SELL | 85% | View Analysis → |
| FDMT | 4D Molecular Therapeutics, Inc. | SELL | 85% | View Analysis → |
| CWLXF | C21 Investments Inc. | SELL | 85% | View Analysis → |
| CMPX | Compass Therapeutics, Inc. | SELL | 85% | View Analysis → |
| CHRS | Coherus Oncology, Inc. | SELL | 85% | View Analysis → |
| CGEM | Cullinan Therapeutics, Inc. | SELL | 85% | View Analysis → |
| NBIX | NEUROCRINE BIOSCIENCES INC | BUY | 84% | View Analysis → |
| MAZE | Maze Therapeutics, Inc. | SELL | 84% | View Analysis → |
| IRIX | IRIDEX CORP | SELL | 84% | View Analysis → |
| IPHYF | Innate Pharma SA | SELL | 84% | View Analysis → |
| GHBWF | Glass House Brands Inc. | SELL | 84% | View Analysis → |
| ENGNW | enGene Holdings Inc. | SELL | 84% | View Analysis → |
| DTIL | PRECISION BIOSCIENCES INC | SELL | 84% | View Analysis → |
| CYAND | CYANOTECH CORP | SELL | 84% | View Analysis → |
| CGTX | COGNITION THERAPEUTICS INC | SELL | 84% | View Analysis → |
| CCCC | C4 Therapeutics, Inc. | SELL | 84% | View Analysis → |
| AUTL | Autolus Therapeutics plc | SELL | 84% | View Analysis → |
| AURA | Aura Biosciences, Inc. | SELL | 84% | View Analysis → |
| LEEEF | Leef Brands Inc. | STRONG SELL | 83% | View Analysis → |
| HUMAW | Humacyte, Inc. | STRONG SELL | 83% | View Analysis → |
| EVAX | Evaxion A/S | SELL | 83% | View Analysis → |
| CGON | CG Oncology, Inc. | SELL | 83% | View Analysis → |
| NXL | Nexalin Technology, Inc. | STRONG SELL | 82% | View Analysis → |
| JSPRW | Jasper Therapeutics, Inc. | STRONG SELL | 82% | View Analysis → |
| NMRA | Neumora Therapeutics, Inc. | SELL | 82% | View Analysis → |
| EXEL | EXELIXIS, INC. | BUY | 82% | View Analysis → |
| CRSP | CRISPR Therapeutics AG | SELL | 82% | View Analysis → |
| APGE | Apogee Therapeutics, Inc. | SELL | 82% | View Analysis → |
| AVXL | ANAVEX LIFE SCIENCES CORP. | SELL | 81% | View Analysis → |
| PASG | Passage BIO, Inc. | STRONG SELL | 80% | View Analysis → |
| KRYS | Krystal Biotech, Inc. | BUY | 80% | View Analysis → |
| KOD | Kodiak Sciences Inc. | SELL | 80% | View Analysis → |
| ELMD | Electromed, Inc. | BUY | 80% | View Analysis → |
| CBLL | Ceribell, Inc. | SELL | 80% | View Analysis → |
| BEAM | Beam Therapeutics Inc. | SELL | 80% | View Analysis → |
| MDT | Medtronic plc | BUY | 80% | View Analysis → |
| NAGE | Niagen Bioscience, Inc. | BUY | 79% | View Analysis → |
| FENC | FENNEC PHARMACEUTICALS INC. | SELL | 79% | View Analysis → |
| SRRK | Scholar Rock Holding Corp | SELL | 78% | View Analysis → |
| SABSW | SAB Biotherapeutics, Inc. | STRONG SELL | 78% | View Analysis → |
| PRME | Prime Medicine, Inc. | STRONG SELL | 78% | View Analysis → |
| PMCB | PharmaCyte Biotech, Inc. | SELL | 78% | View Analysis → |
| IMA | ImageneBio, Inc. | SELL | 78% | View Analysis → |
| HYEX | HEALTHY EXTRACTS INC. | SELL | 78% | View Analysis → |
| RLAY | Relay Therapeutics, Inc. | SELL | 78% | View Analysis → |
| MTEX | MANNATECH INC | SELL | 78% | View Analysis → |
| IVVD | Invivyd, Inc. | SELL | 78% | View Analysis → |
| IPSC | Century Therapeutics, Inc. | SELL | 78% | View Analysis → |
| CRON | Cronos Group Inc. | SELL | 78% | View Analysis → |
| AXGN | Axogen, Inc. | SELL | 78% | View Analysis → |
| LONA | LeonaBio, Inc. | SELL | 77% | View Analysis → |
| LCTX | Lineage Cell Therapeutics, Inc. | SELL | 76% | View Analysis → |
| KYMR | Kymera Therapeutics, Inc. | SELL | 76% | View Analysis → |
| MRNA | Moderna, Inc. | SELL | 76% | View Analysis → |
| CSBR | CHAMPIONS ONCOLOGY, INC. | SELL | 76% | View Analysis → |
| BTMD | biote Corp. | SELL | 76% | View Analysis → |
| RXRX | RECURSION PHARMACEUTICALS, INC. | SELL | 75% | View Analysis → |
| MEHA | Functional Brands Inc. | SELL | 75% | View Analysis → |
| OM | Outset Medical, Inc. | SELL | 74% | View Analysis → |
| NAII | NATURAL ALTERNATIVES INTERNATIONAL INC | SELL | 74% | View Analysis → |
| LENZ | LENZ Therapeutics, Inc. | SELL | 74% | View Analysis → |
| KYTX | Kyverna Therapeutics, Inc. | SELL | 74% | View Analysis → |
| REPL | Replimune Group, Inc. | STRONG SELL | 74% | View Analysis → |
| MRMD | MARIMED INC. | SELL | 74% | View Analysis → |
| FTLF | FITLIFE BRANDS, INC. | BUY | 74% | View Analysis → |
| CNMD | CONMED Corp | SELL | 74% | View Analysis → |
| BDTX | Black Diamond Therapeutics, Inc. | BUY | 74% | View Analysis → |
| SANA | Sana Biotechnology, Inc. | SELL | 72% | View Analysis → |
| HYPR | Hyperfine, Inc. | SELL | 72% | View Analysis → |
| GLUC | Glucose Health, Inc. | STRONG SELL | 72% | View Analysis → |
| BCRX | BIOCRYST PHARMACEUTICALS INC | BUY | 72% | View Analysis → |
| MASI | MASIMO CORP | HOLD | 70% | View Analysis → |
| ITGR | Integer Holdings Corp | HOLD | 70% | View Analysis → |
| FONR | FONAR CORP | HOLD | 70% | View Analysis → |
| IKT | Inhibikase Therapeutics, Inc. | SELL | 69% | View Analysis → |
| GLUE | Monte Rosa Therapeutics, Inc. | HOLD | 69% | View Analysis → |
| PALI | PALISADE BIO, INC. | SELL | 68% | View Analysis → |
| LIVN | LivaNova PLC | HOLD | 68% | View Analysis → |
| BIIB | BIOGEN INC. | HOLD | 68% | View Analysis → |
| NVAX | NOVAVAX INC | SELL | 67% | View Analysis → |
| BLFS | BIOLIFE SOLUTIONS INC | BUY | 67% | View Analysis → |
| IMVT | Immunovant, Inc. | SELL | 66% | View Analysis → |
| IMCR | Immunocore Holdings plc | BUY | 66% | View Analysis → |
| RGEN | REPLIGEN CORP | HOLD | 65% | View Analysis → |
| HCIL | Hongchang International Co., Ltd | SELL | 64% | View Analysis → |
| HALO | HALOZYME THERAPEUTICS, INC. | BUY | 64% | View Analysis → |
| KLRS | Kalaris Therapeutics, Inc. | SELL | 60% | View Analysis → |
| INAB | IN8BIO, INC. | SELL | 58% | View Analysis → |
| AKAN | AKANDA CORP. | SELL | 54% | View Analysis → |
| AYRWF | Ayr Wellness Inc. | SELL | 51% | View Analysis → |
| ARGX | ARGENX SE | BUY | 50% | View Analysis → |
| CGC | Canopy Growth Corp | SELL | 49% | View Analysis → |
| CGEN | COMPUGEN LTD | HOLD | 47% | View Analysis → |
| CLLS | Cellectis S.A. | SELL | 44% | View Analysis → |
| BNTX | BioNTech SE | HOLD | 44% | View Analysis → |
| INMD | InMode Ltd. | HOLD | 42% | View Analysis → |
| EIKN | Eikon Therapeutics, Inc. | HOLD | 41% | View Analysis → |
| ALVOW | Alvotech | HOLD | 40% | View Analysis → |
| EDAP | EDAP TMS SA | HOLD | 39% | View Analysis → |
| CRDL | Cardiol Therapeutics Inc. | HOLD | 39% | View Analysis → |
| RGC | Regencell Bioscience Holdings Ltd | SELL | 22% | View Analysis → |
| MOLN | MOLECULAR PARTNERS AG | HOLD | 18% | View Analysis → |
| MDWD | MediWound Ltd. | SELL | 15% | View Analysis → |
| MEOBF | MESOBLAST LTD | HOLD | 5% | View Analysis → |
Frequently Asked Questions: Biotechnology Stocks
What are the best biotechnology stocks to buy in 2026?
Based on our dual AI fundamental analysis (Claude and ChatGPT), 13 biotechnology stocks have Buy or Strong Buy ratings in 2026. These are ranked by confidence score based on SEC 10-K and 10-Q filing analysis.
Which biotechnology stocks have Strong Buy ratings?
Currently, 0 biotechnology stocks have a Strong Buy rating from our AI analysis. Strong Buy indicates both Claude and ChatGPT agree on exceptional fundamentals with high confidence scores above 80%.
How does AI analyze biotechnology stocks?
Our dual AI system analyzes SEC EDGAR filings including revenue growth, profit margins, ROE, ROA, debt levels, and cash flow. Both Claude (Anthropic) and ChatGPT (OpenAI) independently evaluate each stock, then we combine their ratings for higher accuracy.
What is the AI confidence score?
AI confidence scores range from 0-100% and indicate how strongly the AI models agree on their rating. Higher confidence means clearer signals from SEC filing data. Biotechnology stocks with 80%+ confidence have the most reliable ratings.
Should I invest in biotechnology stocks in 2026?
Our AI analysis shows 13 Buy ratings vs 167 Sell ratings in the biotechnology sector. Individual stock fundamentals vary significantly - review each stock's detailed analysis. This is not investment advice.
How often are biotechnology stock ratings updated?
AI ratings are updated whenever companies file new SEC reports (10-K annually, 10-Q quarterly). Most biotechnology stocks are re-analyzed within 24-48 hours of new filings being published on SEC EDGAR.
What data sources are used for biotechnology stock analysis?
All analysis is based on official SEC EDGAR filings including Form 10-K (annual reports), Form 10-Q (quarterly reports), and other regulatory disclosures. We do not use price data or market sentiment - only fundamental financial data.
Compare Top Biotechnology Stocks
Part of: 💊 Healthcare Sector